Bone Biologics (BBLGW) Total Liabilities (2010 - 2026)

Bone Biologics (BBLGW) has reported Total Liabilities for 17 consecutive years, with $512018.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Liabilities rose 26.07% year-over-year to $512018.0 in Q2 2026; TTM through Jun 2026 was $512018.0, a 26.07% increase from a year earlier, with the FY2025 full-year figure at $418587.0, up 10.82% from the prior year.
• Total Liabilities was $512018.0 for Q2 2026 at Bone Biologics, up from $418587.0 in the prior quarter.
• Over five years, Total Liabilities peaked at $4.0 million in Q1 2023 and troughed at $54913.0 in Q1 2022.
• A 5-year average of $850096.1 and a median of $406142.0 in 2025 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities tumbled 99.61% in 2022 and surged 7204.93% in 2023, its largest moves.
• Over 5 years, Total Liabilities stood at $2.5 million in 2022, then tumbled by 67.37% to $831402.0 in 2023, then slumped by 54.57% to $377712.0 in 2024, then grew by 10.82% to $418587.0 in 2025, then advanced by 22.32% to $512018.0 in 2026.
• The last three Total Liabilities figures came in at $512018.0 (Q2 2026), $418587.0 (Q4 2025), and $334282.0 (Q3 2025), per Business Quant data.